Interleukin(IL)-18 is a pleiotrophic cytokine with functions in immune modulation, angiogenesis and bone metabolism. In this study, the potential of IL-18 as an immunotherapy for prostate cancer (PCa) was examined using the murine model of prostate carcinoma, RM1 and a bone metastatic variant RM1(BM)/B4H7-luc. RM1 and RM1(BM)/B4H7-luc cells were stably transfected to express bioactive IL-18. These cells were implanted into syngeneic immunocompetent mice, with or without an IL-18-neutralising antibody (αIL-18, SK113AE4). IL-18 significantly inhibited the growth of both subcutaneous and orthotopic RM1 tumors and the IL-18 neutralizing antibody abrogated the tumor growth-inhibition. In vivo neutralization of interferon-gamma (IFN-γ) completely eliminated the anti-tumor effects of IL-18 confirming an essential role of IFN-γ as a down-stream mediator of the anti-tumor activity of IL-18. Tumors from mice in which IL-18 and/or IFN-γ was neutralized contained significantly fewer CD4+ and CD8+ T cells than those with functional IL-18. The essential role of adaptive immunity was demonstrated as tumors grew more rapidly in RAG1？/？ mice or in mice depleted of CD4+ and/or CD8+ cells than in normal mice. The tumors in RAG1？/？ mice were also significantly smaller when IL-18 was present, indicating that innate immune mechanisms are involved. IL-18 also induced an increase in tumor infiltration of macrophages and neutrophils but not NK cells. In other experiments, direct injection of recombinant IL-18 into established tumors also inhibited tumor growth, which was associated with an increase in intratumoral macrophages, but not T cells. These results suggest that local IL-18 in the tumor environment can significantly potentiate anti-tumor immunity in the prostate and clearly demonstrate that this effect is mediated by innate and adaptive immune mechanisms.
References
[1]
Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55: 74–108.
[2]
Pienta KJ, Smith DC (2005) Advances in prostate cancer chemotherapy: a new era begins. CA Cancer J Clin 55: 300–318; quiz 323-305.
[3]
Harris DT, Matyas GR, Gomella LG, Talor E, Winship MD, et al. (1999) Immunologic approaches to the treatment of prostate cancer. Semin Oncol 26: 439–447.
[4]
Kowalczyk DW, Wysocki PJ, Mackiewicz A (2003) Cancer immunotherapy using cells modified with cytokine genes. Acta Biochim Pol 50: 613–624.
[5]
Dunn GP, Old LJ, Schreiber RD (2004) The immunobiology of cancer immunosurveillance and immunoediting. Immunity 21: 137–148.
[6]
Matsui K, Yoshimoto T, Tsutsui H, Hyodo Y, Hayashi N, et al. (1997) Propionibacterium acnes treatment diminishes CD4+ NK1.1+ T cells but induces type I T cells in the liver by induction of IL-12 and IL-18 production from Kupffer cells. J Immunol 159: 97–106.
[7]
Okamura H, Tsutsi H, Komatsu T, Yutsudo M, Hakura A, et al. (1995) Cloning of a new cytokine that induces IFN-gamma production by T cells. Nature 378: 88–91.
[8]
Stoll S, Jonuleit H, Schmitt E, Muller G, Yamauchi H, et al. (1998) Production of functional IL-18 by different subtypes of murine and human dendritic cells (DC): DC-derived IL-18 enhances IL-12-dependent Th1 development. Eur J Immunol 28: 3231–3239.
[9]
Stoll S, Muller G, Kurimoto M, Saloga J, Tanimoto T, et al. (1997) Production of IL-18 (IFN-gamma-inducing factor) messenger RNA and functional protein by murine keratinocytes. J Immunol 159: 298–302.
[10]
Pizarro TT, Michie MH, Bentz M, Woraratanadharm J, Smith MF Jr, et al. (1999) IL-18, a novel immunoregulatory cytokine, is up-regulated in Crohn's disease: expression and localization in intestinal mucosal cells. J Immunol 162: 6829–6835.
[11]
Udagawa N, Horwood NJ, Elliott J, Mackay A, Owens J, et al. (1997) Interleukin-18 (interferon-gamma-inducing factor) is produced by osteoblasts and acts via granulocyte/macrophage colony-stimulating factor and not via interferon-gamma to inhibit osteoclast formation. J Exp Med 185: 1005–1012.
[12]
Conti B, Park LC, Calingasan NY, Kim Y, Kim H, et al. (1999) Cultures of astrocytes and microglia express interleukin 18. Brain Res Mol Brain Res 67: 46–52.
Gu Y, Kuida K, Tsutsui H, Ku G, Hsiao K, et al. (1997) Activation of interferon-gamma inducing factor mediated by interleukin-1beta converting enzyme. Science 275: 206–209.
[15]
Ghayur T, Banerjee S, Hugunin M, Butler D, Herzog L, et al. (1997) Caspase-1 processes IFN-gamma-inducing factor and regulates LPS-induced IFN-gamma production. Nature 386: 619–623.
[16]
Nakanishi K, Yoshimoto T, Tsutsui H, Okamura H (2001) Interleukin-18 is a unique cytokine that stimulates both Th1 and Th2 responses depending on its cytokine milieu. Cytokine Growth Factor Rev 12: 53–72.
[17]
Kito T, Kuroda E, Yokota A, Yamashita U (2003) Cytotoxicity in glioma cells due to interleukin-12 and interleukin-18-stimulated macrophages mediated by interferon-gamma-regulated nitric oxide. J Neurosurg 98: 385–392.
[18]
Leung BP, Culshaw S, Gracie JA, Hunter D, Canetti CA, et al. (2001) A role for IL-18 in neutrophil activation. J Immunol 167: 2879–2886.
[19]
Schroder K, Hertzog PJ, Ravasi T, Hume DA (2004) Interferon-gamma: an overview of signals, mechanisms and functions. J Leukoc Biol 75: 163–189.
[20]
Nagai H, Hara I, Horikawa T, Oka M, Kamidono S, et al. (2002) Gene transfer of secreted-type modified interleukin-18 gene to B16F10 melanoma cells suppresses in vivo tumor growth through inhibition of tumor vessel formation. J Invest Dermatol 119: 541–548.
[21]
Tanaka F, Hashimoto W, Robbins PD, Lotze MT, Tahara H (2002) Therapeutic and specific antitumor immunity induced by co-administration of immature dendritic cells and adenoviral vector expressing biologically active IL-18. Gene Ther 9: 1480–1486.
[22]
Yoshimura K, Hazama S, Iizuka N, Yoshino S, Yamamoto K, et al. (2001) Successful immunogene therapy using colon cancer cells (colon 26) transfected with plasmid vector containing mature interleukin-18 cDNA and the Igkappa leader sequence. Cancer Gene Ther 8: 9–16.
[23]
Coughlin CM, Salhany KE, Wysocka M, Aruga E, Kurzawa H, et al. (1998) Interleukin-12 and interleukin-18 synergistically induce murine tumor regression which involves inhibition of angiogenesis. J Clin Invest 101: 1441–1452.
[24]
Kishida T, Asada H, Satoh E, Tanaka S, Shinya M, et al. (2001) In vivo electroporation-mediated transfer of interleukin-12 and interleukin-18 genes induces significant antitumor effects against melanoma in mice. Gene Ther 8: 1234–1240.
[25]
Hikosaka S, Hara I, Miyake H, Hara S, Kamidono S (2004) Antitumor effect of simultaneous transfer of interleukin-12 and interleukin-18 genes and its mechanism in a mouse bladder cancer model. Int J Urol 11: 647–652.
[26]
Wang J, Kobayashi Y, Sato A, Kobayashi E, Murakami T (2004) Synergistic anti-tumor effect by combinatorial gene-gun therapy using IL-23 and IL-18 cDNA. J Dermatol Sci 36: 66–68.
[27]
Micallef MJ, Yoshida K, Kawai S, Hanaya T, Kohno K, et al. (1997) In vivo antitumor effects of murine interferon-gamma-inducing factor/interleukin-18 in mice bearing syngeneic Meth A sarcoma malignant ascites. Cancer Immunol Immunother 43: 361–367.
[28]
Okamoto T, Yamada N, Tsujimura T, Sugihara A, Nishizawa Y, et al. (2004) Inhibition by interleukin-18 of the growth of Dunn osteosarcoma cells. J Interferon Cytokine Res 24: 161–167.
[29]
Subleski JJ, Hall VL, Back TC, Ortaldo JR, Wiltrout RH (2006) Enhanced antitumor response by divergent modulation of natural killer and natural killer T cells in the liver. Cancer Res 66: 11005–11012.
[30]
Osaki T, Peron JM, Cai Q, Okamura H, Robbins PD, et al. (1998) IFN-gamma-inducing factor/IL-18 administration mediates IFN-gamma- and IL-12-independent antitumor effects. J Immunol 160: 1742–1749.
[31]
Cao R, Farnebo J, Kurimoto M, Cao Y (1999) Interleukin-18 acts as an angiogenesis and tumor suppressor. Faseb J 13: 2195–2202.
[32]
Redlinger RE Jr, Mailliard RB, Lotze MT, Barksdale EM Jr (2003) Synergistic interleukin-18 and low-dose interleukin-2 promote regression of established murine neuroblastoma in vivo. J Pediatr Surg 38: 301–307; discussion 301-307.
[33]
Xia D, Zheng S, Zhang W, He L, Wang Q, et al. (2003) Effective induction of therapeutic antitumor immunity by dendritic cells coexpressing interleukin-18 and tumor antigen. J Mol Med 81: 585–596.
[34]
Ju DW, Tao Q, Lou G, Bai M, He L, et al. (2001) Interleukin 18 transfection enhances antitumor immunity induced by dendritic cell-tumor cell conjugates. Cancer Res 61: 3735–3740.
[35]
Tatsumi T, Gambotto A, Robbins PD, Storkus WJ (2002) Interleukin 18 gene transfer expands the repertoire of antitumor Th1-type immunity elicited by dendritic cell-based vaccines in association with therapeutic efficacy. Cancer Res 62: 5853–5858.
[36]
Ju DW, Yang Y, Tao Q, Song WG, He L, et al. (2000) Interleukin-18 gene transfer increases antitumor effects of suicide gene therapy through efficient induction of antitumor immunity. Gene Ther 7: 1672–1679.
[37]
Thompson TC, Southgate J, Kitchener G, Land H (1989) Multistage carcinogenesis induced by ras and myc oncogenes in a reconstituted organ. Cell 56: 917–930.
[38]
Lochner M, Wagner H, Classen M, Forster I (2002) Generation of neutralizing mouse anti-mouse IL-18 antibodies for inhibition of inflammatory responses in vivo. J Immunol Methods 259: 149–157.
[39]
Power CA, Pwint H, Chan J, Cho J, Yu Y, et al. (2009) A novel model of bone-metastatic prostate cancer in immunocompetent mice. Prostate 69: 1613–1623.
[40]
Martiniello-Wilks R, Tsatralis T, Russell P, Brookes DE, Zandvliet D, et al. (2002) Transcription-targeted gene therapy for androgen-independent prostate cancer. Cancer Gene Ther 9: 443–452.
[41]
Giedraitis V, He B, Huang WX, Hillert J (2001) Cloning and mutation analysis of the human IL-18 promoter: a possible role of polymorphisms in expression regulation. J Neuroimmunol 112: 146–152.
[42]
Liu W, Tang Q, Jiang H, Ding X, Liu Y, et al. (2009) Promoter polymorphism of interleukin-18 in angiographically proven coronary artery disease. Angiology 60: 180–185.
[43]
Nong LG, Luo B, Zhang L, Nong HB (2009) Interleukin-18 gene promoter polymorphism and the risk of nasopharyngeal carcinoma in a Chinese population. DNA Cell Biol 28: 507–513.
[44]
Wei YS, Lan Y, Liu YG, Tang H, Tang RG, et al. (2007) Interleukin-18 gene promoter polymorphisms and the risk of esophageal squamous cell carcinoma. Acta Oncol 46: 1090–1096.
[45]
Lebel-Binay S, Thiounn N, De Pinieux G, Vieillefond A, Debre B, et al. (2003) IL-18 is produced by prostate cancer cells and secreted in response to interferons. Int J Cancer 106: 827–835.
[46]
Robertson MJ, Mier JW, Logan T, Atkins M, Koon H, et al. (2006) Clinical and biological effects of recombinant human interleukin-18 administered by intravenous infusion to patients with advanced cancer. Clin Cancer Res 12: 4265–4273.
[47]
Robertson MJ, Kirkwood JM, Logan TF, Koch KM, Kathman S, et al. (2008) A dose-escalation study of recombinant human interleukin-18 using two different schedules of administration in patients with cancer. Clin Cancer Res 14: 3462–3469.
[48]
Tarhini AA, Millward M, Mainwaring P, Kefford R, Logan T, et al. (2009) A phase 2, randomized study of SB-485232, rhIL-18, in patients with previously untreated metastatic melanoma. Cancer 115: 859–868.
[49]
van Herpen CM, Looman M, Zonneveld M, Scharenborg N, de Wilde PC, et al. (2004) Intratumoral administration of recombinant human interleukin 12 in head and neck squamous cell carcinoma patients elicits a T-helper 1 profile in the locoregional lymph nodes. Clin Cancer Res 10: 2626–2635.
[50]
Khorana AA, Rosenblatt JD, Sahasrabudhe DM, Evans T, Ladrigan M, et al. (2003) A phase I trial of immunotherapy with intratumoral adenovirus-interferon-gamma (TG1041) in patients with malignant melanoma. Cancer Gene Ther 10: 251–259.
[51]
Mastrangelo MJ, Maguire HC Jr, Eisenlohr LC, Laughlin CE, Monken CE, et al. (1999) Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanoma. Cancer Gene Ther 6: 409–422.
[52]
Sangro B, Mazzolini G, Ruiz J, Herraiz M, Quiroga J, et al. (2004) Phase I trial of intratumoral injection of an adenovirus encoding interleukin-12 for advanced digestive tumors. J Clin Oncol 22: 1389–1397.
[53]
Bursuker I, North RJ (1984) Generation and decay of the immune response to a progressive fibrosarcoma. II. Failure to demonstrate postexcision immunity after the onset of T cell-mediated suppression of immunity. J Exp Med 159: 1312–1321.
[54]
North RJ, Bursuker I (1984) Generation and decay of the immune response to a progressive fibrosarcoma. I. Ly-1+2- suppressor T cells down-regulate the generation of Ly-1-2+ effector T cells. J Exp Med 159: 1295–1311.
[55]
Komai-Koma M, Gracie JA, Wei XQ, Xu D, Thomson N, et al. (2003) Chemoattraction of human T cells by IL-18. J Immunol 170: 1084–1090.
[56]
Gutzmer R, Langer K, Mommert S, Wittmann M, Kapp A, et al. (2003) Human dendritic cells express the IL-18R and are chemoattracted to IL-18. J Immunol 171: 6363–6371.
[57]
Morel JC, Park CC, Kumar P, Koch AE (2001) Interleukin-18 induces rheumatoid arthritis synovial fibroblast CXC chemokine production through NFkappaB activation. Lab Invest 81: 1371–1383.
[58]
Di Carlo E, Forni G, Lollini P, Colombo MP, Modesti A, et al. (2001) The intriguing role of polymorphonuclear neutrophils in antitumor reactions. Blood 97: 339–345.
[59]
Kikuchi T, Akasaki Y, Joki T, Abe T, Kurimoto M, et al. (2000) Antitumor activity of interleukin-18 on mouse glioma cells. J Immunother 23: 184–189.
